LQT Therapeutics Inc. — ERA-LEARN

Skip to content
Skip to footer

Service Navigation

Home
About
Contact
newsalert

Main Menu Search

Partnerships in a Nutshell
Explore Partnerships
Support for Partnerships
Documents
News and Events
- News
- Events

Home
Partnerships in a Nutshell
Explore Partnerships
Support for Partnerships
Documents
News and Events
- News
- Events

SGK1 inhibition as a novel therapeutic approach in Long QT syndrome

Home
Explore Partnerships
Partnerships
EJP RD
2nd EJP RD Joint Transnational Call for Rare Diseases Research Project (JTC 2020)
SGK1 inhibition as a novel therapeutic approach in Long QT syndrome
LQT Therapeutics Inc.

Full name	LQT Therapeutics Inc.
Short name
Type of organisation
Partner Role	Observer
Country	Canada

Back to project overview

Funded by the European Union under the Grant Agreement no. 101102316. Views and opinions expressed are those of the author(s) only and do not necessarily reflect those of the European Union or the European Commission. Neither the European Union nor the granting authority can be held responsible for them.

Sitemap
Imprint
Privacy Policy
Submit accessibility issues
Accessibility Statement

Follow us on LinkedIn

Use of cookies

We use cookies for statistical purposes and to remember your settings. Please check our privacy and cookies policy.

Use of cookies

We use cookies for statistical purposes and to remember your settings. Please check our privacy and cookies policy.